| Patent Number |
Title Of Patent |
Date Issued |
| 7081334 |
Method for quantifying LBP in body fluids |
July 25, 2006 |
| The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject. |
| 6828418 |
Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions con |
December 7, 2004 |
| Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue |
| 6767893 |
Method of treating conditions associated with intestinal ischemia/reperfusion |
July 27, 2004 |
| The present invention provides methods of treating adverse physiological effects associated with intestinal ischemia/reperfusion by administering to a subject suffering from the effects of intestinal ischemia/reperfusion an effective amount of a BPI protein product. |
| 6759203 |
Method for quantifying BPI in body fluids |
July 6, 2004 |
| The present invention provides a method for quantifying the presence of extracellular BPI in body fluids including blood in a subject comprising conducting a BPI immunoassay on body fluid sample obtained from said subject. |
| 6686332 |
Method of treating depressed reticuloendothelial system function |
February 3, 2004 |
| The present invention provides methods of treating adverse physiological effects associated with depressed reticuloendothelial system function comprising administering to a subject suffering from depressed reticuloendothelial system function an effective amount of a BPI protein produ |
| 6664231 |
Anti-fungal peptides |
December 16, 2003 |
| The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such peptides. |
| 6620785 |
Treatment of Mycobacterial diseases by administration of bactericidal/permeability-increasing pr |
September 16, 2003 |
| The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in com |
| 6599881 |
Antithrombotic materials and methods |
July 29, 2003 |
| Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered. |
| 6599880 |
Bactericidal/permeability-increasing protein (BPI) deletion analogs |
July 29, 2003 |
| Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides |
| 6596691 |
Therapeutic uses of BPI protein products for human meningococcemia |
July 22, 2003 |
| Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered. |
| 6586400 |
Human therapeutic uses of BPI protein products |
July 1, 2003 |
| Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytoki |
| 6583116 |
Anti-chlamydial methods and materials |
June 24, 2003 |
| The present invention relates to methods for treating chlamydial infection comprising administering to a subject suffering from a chlamydial infection a bactericidal permeability-inducing (BPI) protein product. |
| 6482796 |
Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
November 19, 2002 |
| Improved therapeutic uses for N-terminal BPI protein products are described in patients that have BPI-reactive anti-neutrophil cytoplasmic antibodies. |
| 6440936 |
Anti-protozoan methods and materials |
August 27, 2002 |
| The present invention relates to methods for treating protozoan infections comprising administering to a subject suffering from protozoan infection, a bacteriocidal/permeability-inducing (BPI) protein product. |
| 6433140 |
Stable bactericidal permeability-increasing protein products and pharmaceutical compositions con |
August 13, 2002 |
| Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue |
| 6376462 |
Lipopolysaccharide binding protein derivatives |
April 23, 2002 |
| Disclosed are novel biologically active lipopolysaccharide binding protein (LBP) derivatives including LBP derivative hybrid proteins which are characterized by the ability to bind to and neutralize LPS and which lack the CD14-mediated immunostimulatory properties of holo-LBP. |
| 6306824 |
Uses of lipopolysaccharide binding protein |
October 23, 2001 |
| Novel LBP compositions and therapeutic uses for LBP are provided for preventing the adverse effects of exposure to endotoxin. |
| 6277821 |
Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
August 21, 2001 |
| Improved therapeutic compositions, methods and uses of bactericidal/permeability-increasing protein (BPI) products involve use of dimeric forms of BPI protein product monomers characterized by enhanced in vivo biological activity. Preferred formulations include 50 percent or more by |
| 6274348 |
Methods for the preparation of positively charged proteins |
August 14, 2001 |
| Disclosed are novel hybrid fusion proteins comprising at their amino terminus, bactericidal/permeability-increasing protein or a biologically active fragment thereof and, at their carboxy terminus, at least one immunoglobulin heavy chain constant domain useful in treating bacterial i |
| 6274344 |
Methods for recombinant microbial production of fusion proteins and BPI-derived peptides |
August 14, 2001 |
| The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasin |
| 6274328 |
Method for quantifying LBP in body fluids |
August 14, 2001 |
| The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject. |
| 6271203 |
Anti-protozoan methods and materials |
August 7, 2001 |
| The present invention relates to methods for treating protozoan infections comprising administering to a subject suffering from protozoan infection, a bacteriocidal/permeability-inducing (BPI) protein product. |
| 6268345 |
Bactericidal/permeability-increasing protein (BPI) compositions |
July 31, 2001 |
| Bactericidal/permeability increasing protein (BPI) and biologically active fragments, analogs and variants thereof are solubilized by lipid carriers including phospholipids, liposomes and nonionic detergents and stabilized against particle formation by poloxamer surfactants. |
| 6255284 |
Pharmaceutical composition |
July 3, 2001 |
| Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabil |
| 6242418 |
Therapeutic uses of BPI protein products for human meningococcemia |
June 5, 2001 |
| Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered. |
| 6228834 |
Biologically active peptides from functional domains of bactericidal/permeability-increasing pro |
May 8, 2001 |
| The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the |
| 6214789 |
Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing pr |
April 10, 2001 |
| The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in com |
| 6191112 |
Human therapeutic uses of BPI protein products |
February 20, 2001 |
| Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytoki |
| 6162788 |
Uses of BPI protein products |
December 19, 2000 |
| The present invention relates to methods for treating chlamydial infection comprising administering to a subject suffering from a chlamydial infection a bactericidal/permeability-inducing (BPI) protein product. |
| 6156730 |
Anti-fungal peptides |
December 5, 2000 |
| The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such peptides. |
| 6153730 |
Biologically active peptides from functional domains of bactericidal/permeability-increasing pro |
November 28, 2000 |
| The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the |
| 6146850 |
Proteins encoding gelonin sequences |
November 14, 2000 |
| The present invention provides purified proteins that contain gelonin amino acid sequences that have enzymatic activity. |
| 6146631 |
Immunotoxins comprising ribosome-inactivating proteins |
November 14, 2000 |
| The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transform |
| 6140306 |
Method of treating gram-negative bacterial infection by administration of bactericidal/permeabil |
October 31, 2000 |
| The present invention relates to methods and compositions for treating gram-negative bacterial infections, using BPI protein products. Co-treatment, or concurrent administration, of BPI protein product with an antibiotic in treatment of gram-negative bacterial infections improves the |
| 6107280 |
Antithrombotic materials and methods |
August 22, 2000 |
| Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered. |
| 6087126 |
Bactericidal/permeability-increasing protein (BPI) deletion analogs |
July 11, 2000 |
| Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides |
| 6066620 |
Pharmaceutical compositions of bactericidal/permeability increasing protein (BPI) |
May 23, 2000 |
| Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabil |
| 6057293 |
Bactericidal/permeability-increasing protein (BPI) compositions |
May 2, 2000 |
| Bactericidal/permeability increasing protein (BPI) and biologically active fragments, analogs and variants thereof are solubilized by lipid carriers including phospholipids, liposomes and nonionic detergents and stabilized against particle formation by poloxamer surfactants. |
| 6054431 |
Anti-gram-positive bacterial methods and materials |
April 25, 2000 |
| The present invention relates to methods of treating gram-positive bacterial infections by administration of a BPI protein product alone, or in combination with an antibiotic. BPI protein product alone has a bactericidal or growth inhibitory effect on selected gram-positive organisms |
| 6051553 |
Method for potentiating BPI protein product bactericidal activity by administration of LBP prote |
April 18, 2000 |
| The present invention provides methods of potentiating the gram-negative bactericidal activity of BPI protein products by means of administering LBP protein products. |
| 6017881 |
Method of treating conditions associated with intestinal ischemia/reperfusion |
January 25, 2000 |
| The present invention provides methods of treating adverse physiological effects associated with intestinal ischemia/reperfusion by administering to a subject suffering from the effects of intestinal ischemia/reperfusion an effective amount of a BPI protein product. |
| 6013631 |
Bactericidal/permeability-increasing protein (BPI) deletion analogs |
January 11, 2000 |
| Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides |
| 6013629 |
Anti-protozoan methods and materials |
January 11, 2000 |
| The present invention relates to methods for treating protozoan infections comprising administering to a subject suffering from protozoan infection, a bacteriocidal/permeability-inducing (BPI) protein product. |
| 5990086 |
Therapeutic uses of BPI protein products for human meningococcemia |
November 23, 1999 |
| Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered. |
| 5990082 |
Uses of lipopolysaccharide binding protein |
November 23, 1999 |
| Novel LBP compositions and therapeutic uses for LBP are provided for preventing the adverse effects of exposure to endotoxin. |
| 5955427 |
Pharmaceutical composition |
September 21, 1999 |
| Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabil |
| 5952302 |
Human therapeutic uses of BPI protein products |
September 14, 1999 |
| Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytoki |
| 5945399 |
Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma |
August 31, 1999 |
| Methods and materials for the treatment of humans suffering from hemorrhage due to trauma are provided, in which therapeutically effective amounts of BPI protein products are administered. |
| 5935930 |
Antithrombotic materials and methods |
August 10, 1999 |
| Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered. |
| 5932544 |
Bactericidal/permeability-increasing protein (BPI) compositions |
August 3, 1999 |
| Bactericidal/permeability increasing protein (BPI) and biologically active fragments, analogs and variants thereof are solubilized by lipid carriers including phospholipids, liposomes and nonionic detergents and stabilized against particle formation by poloxamer surfactants. |
